• Akebia flagged upcoming clinical updates at ASN Kidney Week 2026 in Denver on October 21-25.
• U.S. Renal Care will present VOICE trial results on October 23 comparing three-times-weekly vadadustat with an ESA in hemodialysis anemia.
• The readout will focus on safety outcomes, positioning an alternate dosing approach for Vafseo in dialysis settings.
• Conference posters will also outline Phase 2 work in FSGS for praliciguat, alongside a Phase 2 basket trial of ebribafusp alfa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840424) on October 06, 2026, and is solely responsible for the information contained therein.